MannKind Corporation of Santa Clarita announced Thursday that it earned a milestone payment of $50 million in payments from its licensing agreement with Sanofi.
Previously, MannKind received a $150 million upfront payment when the agreement was made for Sanofi to take the biomedical device company’s diabetes inhaler treatment Afrezza to market.
MannKind is also eligible to earn up to $725 million in further development, regulatory and sales milestones, and is also eligible to receive a share of profits on sales of Afrezza.
